Which has stronger valuation & earnings, BIIB or CYTK?

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.19 $1.29B $5.65 38.37 Cytokinetics $88.04M 108.60 -$784.96M -$7.22 N/A

Is BIIB or CYTK more profitable?

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Cytokinetics -1,321.12% N/A -51.01%

Does the media prefer BIIB or CYTK?

In the previous week, Biogen had 20 more articles in the media than Cytokinetics. MarketBeat recorded 28 mentions for Biogen and 8 mentions for Cytokinetics. Biogen's average media sentiment score of 1.35 beat Cytokinetics' score of 0.65 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or CYTK?

In the previous week, Alnylam Pharmaceuticals had 17 more articles in the media than Cytokinetics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 8 mentions for Cytokinetics. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Cytokinetics' score of 0.65 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, INSM or CYTK?

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.29 -$1.28B -$4.11 N/A Cytokinetics $88.04M 108.60 -$784.96M -$7.22 N/A

Is INSM or CYTK more profitable?

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Cytokinetics -1,321.12% N/A -51.01%

Does the media prefer ROIV or CYTK?

In the previous week, Roivant Sciences had 11 more articles in the media than Cytokinetics. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.65 beat Roivant Sciences' score of 0.40 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, INCY or CYTK?

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.04 $1.29B $7.85 16.28 Cytokinetics $88.04M 108.60 -$784.96M -$7.22 N/A

Is INCY or CYTK more profitable?

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Cytokinetics -1,321.12% N/A -51.01%

Does the media refer more to INCY or CYTK?

In the previous week, Incyte had 19 more articles in the media than Cytokinetics. MarketBeat recorded 27 mentions for Incyte and 8 mentions for Cytokinetics. Incyte's average media sentiment score of 1.11 beat Cytokinetics' score of 0.65 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 18 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$76.84 -0.34 (-0.44%)

As of 08/21/2026 04:00 PM Eastern

Compare

CYTK vs. BIIB, ALNY, INSM, ROIV, and INCY

Should you buy Cytokinetics stock or one of its competitors? Cytokinetics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cytokinetics compare to Biogen?

Biogen (NASDAQ:BIIB) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Biogen presently has a consensus target price of $227.07, indicating a potential upside of 4.75%. Cytokinetics has a consensus target price of $102.20, indicating a potential upside of 33.00%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Cytokinetics	-1,321.12%	N/A	-51.01%

87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

In the previous week, Biogen had 20 more articles in the media than Cytokinetics. MarketBeat recorded 28 mentions for Biogen and 8 mentions for Cytokinetics. Biogen's average media sentiment score of 1.35 beat Cytokinetics' score of 0.65 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Alnylam Pharmaceuticals had 17 more articles in the media than Cytokinetics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 8 mentions for Cytokinetics. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Cytokinetics' score of 0.65 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals presently has a consensus target price of $386.62, suggesting a potential upside of 63.67%. Cytokinetics has a consensus target price of $102.20, suggesting a potential upside of 33.00%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Alnylam Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Cytokinetics' net margin of -1,321.12%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Cytokinetics	-1,321.12%	N/A	-51.01%

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Cytokinetics on 13 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Insmed (NASDAQ:INSM) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Insmed presently has a consensus price target of $205.52, indicating a potential upside of 63.41%. Cytokinetics has a consensus price target of $102.20, indicating a potential upside of 33.00%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

In the previous week, Cytokinetics had 8 more articles in the media than Insmed. MarketBeat recorded 8 mentions for Cytokinetics and 0 mentions for Insmed. Insmed's average media sentiment score of 1.84 beat Cytokinetics' score of 0.65 indicating that Insmed is being referred to more favorably in the media.

Company	Overall Sentiment
Insmed	Very Positive
Cytokinetics	Positive

Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Cytokinetics	-1,321.12%	N/A	-51.01%

Summary

Insmed beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Roivant Sciences had 11 more articles in the media than Cytokinetics. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.65 beat Roivant Sciences' score of 0.40 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,174.36	-$299.77M	-$0.53	N/A
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

Cytokinetics has a net margin of -1,321.12% compared to Roivant Sciences' net margin of -3,534.96%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Cytokinetics	-1,321.12%	N/A	-51.01%

Roivant Sciences currently has a consensus target price of $35.14, suggesting a potential downside of 3.21%. Cytokinetics has a consensus target price of $102.20, suggesting a potential upside of 33.00%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Roivant Sciences beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Incyte?

Incyte (NASDAQ:INCY) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Incyte had 19 more articles in the media than Cytokinetics. MarketBeat recorded 27 mentions for Incyte and 8 mentions for Cytokinetics. Incyte's average media sentiment score of 1.11 beat Cytokinetics' score of 0.65 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	18 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.04	$1.29B	$7.85	16.28
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Cytokinetics	-1,321.12%	N/A	-51.01%

Incyte currently has a consensus target price of $123.10, suggesting a potential downside of 3.69%. Cytokinetics has a consensus target price of $102.20, suggesting a potential upside of 33.00%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.48
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Incyte beats Cytokinetics on 12 of the 16 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.56B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-10.64	11.62	272.60	24.25
Price / Sales	108.60	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	-55.28	16.80	13.05	6.20
Net Income	-$784.96M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.66%	3.29%	2.09%	0.08%
1 Month Performance	-6.20%	8.23%	6.64%	3.88%
1 Year Performance	100.42%	55.05%	25.02%	16.98%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	3.3677 of 5 stars	$76.84 -0.4%	$102.20 +33.0%	+100.4%	$9.56B	$88.04M	N/A	250	Insider Trade
BIIB Biogen	3.9629 of 5 stars	$207.13 -0.4%	$224.61 +8.4%	+55.6%	$30.72B	$10.03B	36.66	7,500	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.9363 of 5 stars	$216.98 -1.0%	$396.72 +82.8%	-48.0%	$29.33B	$4.80B	40.33	2,770	News Coverage Analyst Upgrade
INSM Insmed	3.4506 of 5 stars	$134.75 +2.8%	$205.52 +52.5%	-4.6%	$28.63B	$606.42M	N/A	1,664
ROIV Roivant Sciences	1.5285 of 5 stars	$35.78 -1.5%	$35.14 -1.8%	+204.5%	$26.14B	$8.26M	N/A	860	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors